Who We Are
Opti-Mol Consulting, LLC provides medicinal chemistry and drug discovery consulting services for preclinical drug discovery programs. The Principal Consultant and Founder is Dr. Brad Henke, an accomplished scientist with over 24 years of experience in the pharmaceutical industry. Prior to establishing Opti-Mol Consulting, Dr. Henke was a Director of Chemistry at GlaxoSmithKline (GSK) in Research Triangle Park, North Carolina, where he was accountable for leading medicinal chemistry divisions in both metabolic diseases (e.g. diabetes, obesity) and skeletal muscle diseases. Dr. Henke has a strong background in organic and medicinal chemistry, drug discovery program leadership, technical due diligence work, and strategic planning of preclinical research programs from initial lead generation through Phase 1b/2a clinical trials. He has knowledge and experience in structure- and fragment-based drug design, pharmacophore mapping, structure-activity relationship analysis, chemoproteomics, in vitro and cell-based screening, in vivo pharmacology, pharmacokinetics, non-clinical toxicology, and has experience with both small molecule- and peptide-based discovery programs.
Dr. Henke received his B. S. degree in Chemistry from Miami University (OH), graduating summa cum laude. He received his Ph.D. in Synthetic Organic Chemistry from the University of Illinois under the direction of Professor Scott E. Denmark. He was the recipient of an American Cancer Society Postdoctoral Fellowship and did postgraduate work at the University of California, Berkeley under the direction of Professor Clayton H. Heathcock. In 1991 he was recruited to join GSK (then Glaxo, Inc.) in Research Triangle Park, North Carolina as a medicinal chemist.
In his 23 years with GSK, Dr. Henke managed, led, or was a team member of, multidisciplinary preclinical program teams that produced over 10 clinical candidates that reached Phase I clinical trials or beyond. He is the inventor of Farglitazar, a PPAR-gamma agonist that reached Phase III clinical trials for the treatment of type 2 diabetes, and GI165638X, a selective estrogen receptor modulator that was out-licensed to Duke University for oncology applications. Dr. Henke was a member of GSK's therapeutic in-licensing team that conducted numerous due diligences and technical evaluations of preclinical and clinical stage assets in the metabolic diseases therapy area. In addition, Dr. Henke was Chair of GSK's Global Chemistry-IT Strategy Team, which developed, evaluated, and implemented strategic chemoinformatics solutions designed to improve desktop applications for GSK chemists company-wide. Dr. Henke also led a global multidisciplinary team that designed and implemented a novel, proprietary tool that GSK scientists use to quantitatively evaluate and score the attrition risk of clinical drug candidates.
Dr. Henke has over 35 peer-reviewed publications and patents in his scientific career and has been an invited lecturer at over 30 universities and scientific meetings. In addition to the consulting work with his clients, Dr. Henke currently serves on the Scientific Advisory Board of AsedaSciences, INC., as a Catalyst in the Biopharmaceuticals Division of the University of Wisconsin Alumni Research Foundation Accelerator Program, and as a Technical Advisory Panel member for the University of North Carolina KickStart Program for biomedical technologies. He is a member of the American Chemical Society. You can view his profile on LinkedIn.